Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Enliven Therapeutics (ELVN) Invested Capital (2019 - 2026)

Enliven Therapeutics has reported Invested Capital over the past 8 years, most recently at $453.4 million for Q1 2026.

  • Quarterly results put Invested Capital at $453.4 million for Q1 2026, up 57.26% from a year ago — trailing twelve months through Mar 2026 was $453.4 million (up 57.26% YoY), and the annual figure for FY2025 was $459.6 million, up 48.33%.
  • Invested Capital reached $453.4 million in Q1 2026 per ELVN's latest filing, down from $459.6 million in the prior quarter.
  • Across five years, Invested Capital topped out at $488.5 million in Q2 2025 and bottomed at -$76.8 million in Q4 2022.
  • Median Invested Capital over the past 5 years was $288.4 million (2024), compared with a mean of $247.7 million.
  • The largest annual shift saw Invested Capital crashed 190.37% in 2022 before it soared 675.81% in 2023.
  • Over 5 years, Invested Capital stood at -$76.8 million in 2022, then soared by 420.09% to $245.9 million in 2023, then increased by 26.0% to $309.8 million in 2024, then skyrocketed by 48.33% to $459.6 million in 2025, then decreased by 1.36% to $453.4 million in 2026.
  • Business Quant data shows Invested Capital for ELVN at $453.4 million in Q1 2026, $459.6 million in Q4 2025, and $476.1 million in Q3 2025.